The introduction and widespread adoption of PSA has revolutionized the way prostate
cancer is diagnosed and treated. However, the use of PSA has also led to over-diagnosis …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

The introduction and widespread adoption of prostate-specific antigen (PSA) has
revolutionized the way prostate cancer is diagnosed and treated. However, the use of PSA …

Since the introduction of serum prostate-specific antigen (PSA) screening 25 years ago,
prostate cancer diagnosis and management have been guided by this biomarker. Yet, PSA …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been
employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved …

The detection and treatment of prostate cancer was dramatically altered with the advent of
the prostate-specific antigen (PSA), and its usefulness particularly in following patients after …

The widespread use of the PSA test has led to increased detection of the disease at earlier
stages and a reduction in the number of patients where metastatic disease is found at …

Prostate-specific antigen (PSA) is widely used as a biomarker in the detection of prostate
cancer and for decision making regarding treatment options, response to therapy, and …

In the 1990s the discovery of prostate-specific antigen (PSA) revolutionized early prostate
cancer detection. Since that time, PSA has become an indispensable marker for diagnosis …